全球医药领先品牌_肿瘤特效药_抗癌新药_靶向药物_全球医药咨询-【健康光环全球医药】 -

Sotorasib, a specific inhibitor of oral KRAS G12C launched by Amgen in the United States, was approved for marketing for the first time under the accelerated channel of the US FDA on May 28, 2021. It was first used to treat patients with KRAS Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with G12C mutations mark the advent of oral targeted therapy for KRAS-mutated lung cancer. ‌

Check Details

1
2
...
4141
4142
4143
4144
4145
4146
4147
4148
4149
4150

Menu

Oncology

Side effects and common adverse reactions of Lurbinectedin

Detailed instructions for Lurbinectedin: indications, usage and dosage, side effects and precautions

Chinese instructions for rubidine (Zepzelca)

Detailed instructions for Durvalumab: indications, usage and dosage, side effects and precautions

Tarlatamab FDA Approved for Treatment of Extensive Stage Small Cell Lung Cancer

Tarlatamab usage and dosage: recommended dosage, special populations and delayed dosing dosage adjustments

Side effects and common adverse reactions of Tarlatamab

Detailed instructions for Tarlatamab

Tarlatamab (Tarlatamab) Chinese instruction manual: indications, usage and dosage, adverse reactions, precautions

How to alleviate the side effects of Ripotinib

Side effects and precautions of Ripotinib

Detailed instructions for Sotorasib: indications, usage and dosage, side effects, precautions

Category

相关知识